Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Theraclion SAS, Paris, France | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to test an investigational device called the Echopulse for treatment of breast fibroadenomas in women. Fibroadenomas are benign (noncancerous) breast tumors that are made of glandular and fibrous breast tissue. These lumps can occur alone, in groups, or as a complex of lumps together. Sometimes women feel these in the breast when doing regular self breast exams, or they may be found during a routine mammogram. Some are small (less than an inch in size), and others are quite large (the size of a lemon or larger).
This is a study about the Echopulse device, a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast). The high intensity focused ultrasound (HIFU) heats the targeted site which causes the cells to die and allows the possibility to treat the fibroadenoma without the need for surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIFU treatment | Experimental | The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High Intensity Focused Ultrasound | Device | The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast). |
| Measure | Description | Time Frame |
|---|---|---|
| Change in volume of fibroadenoma | Fibroadenoma volume with be measured by ultrasound. | baseline, 3, 6, and 12 months |
| Size of fibroadenoma | Fibroadenoma will be assessed by physical examination including measurement of tumor size at clinic visits. | baseline, 3, 6, and 12 months |
| Patient reported outcomes | Patient-rated pain and patient responses to Satisfaction Questionnaire will be measured at intervals up to 12 months following HIFU treatment session | up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse events | up to 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Brenin, MD | University of Virginia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Virginia Health System | Charlottesville | Virginia | 22908 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Oct 21, 2021 | |
| Reset | Nov 18, 2021 | |
| Release | Mar 9, 2026 | |
| Reset | Mar 27, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Oct 21, 2021 | Nov 18, 2021 | |||
| Mar 9, 2026 |
| ID | Term |
|---|---|
| D018226 | Fibroadenoma |
| ID | Term |
|---|---|
| D018225 | Neoplasms, Fibroepithelial |
| D018218 | Neoplasms, Fibrous Tissue |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Mar 27, 2026 |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |